Desquinolinyl Lenvatinib CAS 796848-79-8 Puritas >99.0% (HPLC) Lenvatinib Mesylate Factory intermedia
Ruifu Chemical Supple Lenvatinib Mesylate media cum puritate
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylatus CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus CAS 205448-66-4
Nomen chemicum | 1-(2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea |
Synonyma | Desquinolinyl Lenvatinib;Lenvatinib immunditia 16;Lenvatinib Desquinolinyl Impurity;Lenvatinib immunditia LFS-A;Lenvatinib Mesylate Medium Ⅲ;N-(2-Chloro-4-Hydroxyphenyl)-N'-Cyclopropyl-Urea |
CAS Number | 796848-79-8 |
CATTUS Number | RF-PI1972 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C10H11ClN2O2 |
M. Pondus | 226.66 |
Ferveret | 364.6±42.0℃ |
Density | 1.43±0.10 g/cm3 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Off-White ad Reddish solidus Pulvis |
Puritas / Analysis Methodus | >99.0% (HPLC) |
Humor (KF) | <0.50% |
Residere in Ignition | <0.20% |
una immunditia | <0.50% |
Totalis immunditias | <1.00% |
Metalla gravis | <10ppm |
Infrared Imaginis | Conformat ut Structure |
NMR | Conformat ut Structure |
Test Standard | Enterprise Standard |
Consuetudinem | Medium de Mesylate Lenvatinib (CAS: 857890-39-2) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea, quae etiam Desquinolinyl Lenvatinib nota est, (CAS: 796848-79-8) medium seu immundum Mesylate Lenvatinib (CAS: 857890-39-2).Desquinolinyl Lenvatinib metabolita est de Mesylate Lenvatinib quae viva voce inhibitor est multiplicium receptarum tyrosinae kinasium receptarum VEGF, FGF, SCF receptorum.Lenvatinib medicamento est anti-cancer ad curationem quarundam generis cancri thyroideae, et in potentia ad alias carcinomata.Die 13 Februarii 2015, US FDA approbavit anticancer medicamentum Lenvatinib ad curationem cancri thyreici.Lenvatinib inhibitor enzyme multiplex est, cum possit inhibere VEGFR2 et VEGFR3 (vascularis incrementi endothelialis factor receptor).Nomen artis Lenvatinib est Lenvima.